Kiora Pharmaceuticals, Inc.
5 clinical trials · Sponsor
◉ Watch Kiora Pharmaceuticals, Inc.
| Record | Firm | Date |
|---|---|---|
| A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa (NCT06628947) | Kiora Pharmaceuticals, Inc. | 2025-08-29 |
| Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema (NCT06825702) | Kiora Pharmaceuticals, Inc. | 2025-05-01 |
| A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease (NCT05629364) | Kiora Pharmaceuticals, Inc. | 2023-03-15 |
| A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) (NCT05282953) | Kiora Pharmaceuticals, Inc. | 2022-11-10 |
| A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects (NCT05436288) | Kiora Pharmaceuticals, Inc. | 2022-07-01 |
Track Kiora Pharmaceuticals, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.